[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1125929T3 - Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester - Google Patents

Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester

Info

Publication number
DK1125929T3
DK1125929T3 DK00310064T DK00310064T DK1125929T3 DK 1125929 T3 DK1125929 T3 DK 1125929T3 DK 00310064 T DK00310064 T DK 00310064T DK 00310064 T DK00310064 T DK 00310064T DK 1125929 T3 DK1125929 T3 DK 1125929T3
Authority
DK
Denmark
Prior art keywords
trifluoromethyl
methoxycarbonylamino
quinoline
dihydro
benzyl
Prior art date
Application number
DK00310064T
Other languages
Danish (da)
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1125929T3 publication Critical patent/DK1125929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00310064T 1999-11-30 2000-11-13 Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester DK1125929T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
DK1125929T3 true DK1125929T3 (da) 2006-04-03

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00310064T DK1125929T3 (da) 1999-11-30 2000-11-13 Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester

Country Status (45)

Country Link
US (1) US6313142B1 (zh)
EP (1) EP1125929B1 (zh)
JP (1) JP3579345B2 (zh)
KR (1) KR100408177B1 (zh)
CN (1) CN1173953C (zh)
AP (1) AP2000002011A0 (zh)
AR (1) AR029775A1 (zh)
AT (1) ATE315028T1 (zh)
AU (1) AU784694B2 (zh)
BG (1) BG105009A (zh)
BR (1) BR0005636A (zh)
CA (1) CA2327029C (zh)
CO (1) CO5261552A1 (zh)
CY (1) CY1104989T1 (zh)
CZ (1) CZ20004407A3 (zh)
DE (1) DE60025317T2 (zh)
DK (1) DK1125929T3 (zh)
DZ (1) DZ3079A1 (zh)
EA (1) EA003668B1 (zh)
EE (1) EE200000659A (zh)
ES (1) ES2254109T3 (zh)
GE (1) GEP20022798B (zh)
GT (1) GT200000190A (zh)
HK (1) HK1038007A1 (zh)
HN (1) HN2000000203A (zh)
HR (1) HRP20000804A2 (zh)
HU (1) HUP0004747A3 (zh)
ID (1) ID28489A (zh)
IL (1) IL139849A (zh)
IS (1) IS5715A (zh)
MA (1) MA25223A1 (zh)
NO (1) NO20006039L (zh)
NZ (1) NZ508509A (zh)
OA (1) OA11494A (zh)
PA (1) PA8503801A1 (zh)
PE (1) PE20010913A1 (zh)
PL (1) PL344208A1 (zh)
SG (1) SG102603A1 (zh)
SK (1) SK17792000A3 (zh)
TN (1) TNSN00230A1 (zh)
TW (1) TW591016B (zh)
UA (1) UA65615C2 (zh)
UY (1) UY26451A1 (zh)
YU (1) YU71500A (zh)
ZA (1) ZA200006947B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
ATE410521T1 (de) * 2002-04-11 2008-10-15 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004032848A2 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE461700T1 (de) 2002-12-20 2010-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
EP2289507A1 (en) * 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmaceutical compositions of CETP inhibitors
WO2004082675A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
ES2332051T3 (es) * 2003-10-08 2010-01-25 Eli Lilly And Company Compuestos y procedimientos para tratar dislipidemia.
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
TW202409008A (zh) 2022-07-05 2024-03-01 荷蘭商新阿姆斯特丹製藥公司 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (zh) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
EP1125929B1 (en) 2006-01-04
NO20006039D0 (no) 2000-11-29
NO20006039L (no) 2001-05-31
DE60025317T2 (de) 2006-08-03
EP1125929A1 (en) 2001-08-22
TW591016B (en) 2004-06-11
EA003668B1 (ru) 2003-08-28
CA2327029C (en) 2005-08-09
AP2000002011A0 (en) 2000-12-31
KR20010052012A (ko) 2001-06-25
GT200000190A (es) 2002-04-27
IL139849A0 (en) 2002-02-10
MA25223A1 (fr) 2001-07-02
ID28489A (id) 2001-05-31
SK17792000A3 (sk) 2002-10-08
IS5715A (is) 2001-05-31
CY1104989T1 (el) 2010-03-03
KR100408177B1 (ko) 2003-12-01
ES2254109T3 (es) 2006-06-16
JP2001163859A (ja) 2001-06-19
NZ508509A (en) 2001-06-29
UY26451A1 (es) 2001-06-29
DE60025317D1 (de) 2006-03-30
CA2327029A1 (en) 2001-05-30
YU71500A (sh) 2003-02-28
OA11494A (en) 2004-05-07
EA200001129A2 (ru) 2001-06-25
HUP0004747A2 (hu) 2001-10-28
PE20010913A1 (es) 2001-09-10
ATE315028T1 (de) 2006-02-15
EE200000659A (et) 2001-08-15
AU784694B2 (en) 2006-06-01
HUP0004747A3 (en) 2002-12-28
HN2000000203A (es) 2001-06-13
HU0004747D0 (zh) 2001-02-28
UA65615C2 (uk) 2004-04-15
ZA200006947B (en) 2002-05-27
CN1173953C (zh) 2004-11-03
PA8503801A1 (es) 2002-07-30
DZ3079A1 (fr) 2004-10-24
BG105009A (en) 2001-11-30
AU7178900A (en) 2001-05-31
IL139849A (en) 2006-10-31
US6313142B1 (en) 2001-11-06
TNSN00230A1 (fr) 2005-11-10
CN1302800A (zh) 2001-07-11
HK1038007A1 (en) 2002-03-01
CO5261552A1 (es) 2003-03-31
SG102603A1 (en) 2004-03-26
HRP20000804A2 (en) 2001-06-30
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
CZ20004407A3 (cs) 2002-06-12
BR0005636A (pt) 2001-07-17
AR029775A1 (es) 2003-07-16
EA200001129A3 (ru) 2001-10-22
GEP20022798B (en) 2002-09-25

Similar Documents

Publication Publication Date Title
DK1125929T3 (da) Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
TR199900400T2 (xx) Heterosiklik metaloproteaz inhibit�rleri.
DE60000708D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
TR199900382T2 (xx) Heterosiklik metaloproteaz inhibit�rleri.
EE200200365A (et) (RR,SS)-3-(2-dimetüülaminometüül-1-hüdroksütsükloheksüül)fenüül-2-hüdroksübens oaadist tulenevad estrid
DE60021308D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
TR199900429T2 (xx) Spirosiklik metaloproteaz inhibit�rleri.
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
ID28447A (id) Proses polimerisasi kontinu pembuatan poliamida-poliamida dari omega-aminonitril
DK0839138T3 (da) Fremgangsmåde til fremstilling af N-substituerede 3-hydroxypyrazoler
TR200000720T2 (tr) Kuinolin türevlerinin sentezi için metod.
DK1165503T3 (da) Fremgangsmåde til fremstilling af hydroxymethylthiosmörsyreesthere
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DE60001599D1 (de) Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin
DE69936186D1 (de) Dihydroartemisinin-Formulierung zur Behandlung von verschiedenen Typen von Malaria
DK0871616T3 (da) Fremgangsmåde til fremstilling af lægemidler mod malaria
DE69907865D1 (de) Verfahren zu Herstellung von 3-Alkyl-3-Hydroxymethyloxetanen
DE60043610D1 (de) Verfahren zur herstellung von l-lysin
DE60001282D1 (de) Verfahren zur Herstellung von Hydroxyalkyl (Meth)acrylaten
DK1202949T3 (da) Fremgangsmåde til fremstilling af acylerede 1,3-dicarbonylforbindelser
NO20016390D0 (no) Fremgangsmåte for fremstilling av (-)-(1S,4R) N-beskyttede 4- amino-2-cyklopenten-1-karboksylatestere
DE60221500D1 (de) Verfahren zur herstellung von fibraten
DE50100478D1 (de) Verfahren zur Herstellung von Esterquats